Becker H, Seidler U
Pflugers Arch. 2024; 476(4):593-610.
PMID: 38374228
PMC: 11006743.
DOI: 10.1007/s00424-024-02914-3.
Calthorpe R, Rosenfeld M, Goss C, Green N, Derleth M, Carr S
J Cyst Fibros. 2024; 23(4):746-753.
PMID: 38342635
PMC: 11315808.
DOI: 10.1016/j.jcf.2024.01.011.
Yu B, Yu Y, Wang X, Xu C, Xiao Y
Pediatr Investig. 2023; 7(4):268-276.
PMID: 38050536
PMC: 10693666.
DOI: 10.1002/ped4.12404.
Patel D, Baliss M, Saikumar P, Numan L, Teckman J, Hachem C
Int J Mol Sci. 2023; 24(21).
PMID: 37958749
PMC: 10648514.
DOI: 10.3390/ijms242115766.
Sankararaman S, Schindler T
Pediatric Health Med Ther. 2023; 14:361-378.
PMID: 37908317
PMC: 10615098.
DOI: 10.2147/PHMT.S402589.
Acute Pancreatitis in a Previously Exocrine Pancreatic Insufficient Cystic Fibrosis Patient Who Had Improved Pancreatic Function After Being Treated With Lumacaftor/Ivacaftor.
Redman A, Yoo M, Freswick P, Thompson K
JPGN Rep. 2023; 2(3):e096.
PMID: 37205952
PMC: 10191563.
DOI: 10.1097/PG9.0000000000000096.
Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine.
Ritivoiu M, Dragoi C, Matei D, Stan I, Nicolae A, Craiu M
Pharmaceutics. 2023; 15(1).
PMID: 36678791
PMC: 9862205.
DOI: 10.3390/pharmaceutics15010162.
The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review.
McKay I, Ooi C
Front Pediatr. 2022; 10:914790.
PMID: 35832587
PMC: 9271761.
DOI: 10.3389/fped.2022.914790.
Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study.
Migliorisi G, Collura M, Ficili F, Pensabene T, Bongiorno D, Collura A
Pharmaceuticals (Basel). 2022; 15(5).
PMID: 35631432
PMC: 9145356.
DOI: 10.3390/ph15050606.
Current clinical opinion on CFTR dysfunction and patient risk of pancreatitis: diagnostic and therapeutic considerations.
Phadke M, Sellers Z
Expert Rev Gastroenterol Hepatol. 2022; 16(6):499-509.
PMID: 35623009
PMC: 9256802.
DOI: 10.1080/17474124.2022.2084072.
An Update on CFTR Modulators as New Therapies for Cystic Fibrosis.
King J, Nichols A, Bentley S, Carr S, Davies J
Paediatr Drugs. 2022; 24(4):321-333.
PMID: 35570261
DOI: 10.1007/s40272-022-00509-y.
Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study.
Olsen M, Kjoller-Svarre M, Moller G, Katzenstein T, Nielsen B, Pressler T
Nutrients. 2022; 14(7).
PMID: 35405943
PMC: 9003007.
DOI: 10.3390/nu14071330.
Increasing life expectancy in cystic fibrosis: Advances and challenges.
McBennett K, Davis P, Konstan M
Pediatr Pulmonol. 2021; 57 Suppl 1:S5-S12.
PMID: 34672432
PMC: 9004282.
DOI: 10.1002/ppul.25733.
New Therapies to Correct the Cystic Fibrosis Basic Defect.
Bergeron C, Cantin A
Int J Mol Sci. 2021; 22(12).
PMID: 34201249
PMC: 8227161.
DOI: 10.3390/ijms22126193.
Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor.
Petrocheilou A, Kaditis A, Loukou I
Children (Basel). 2020; 7(1).
PMID: 31940891
PMC: 7022767.
DOI: 10.3390/children7010006.
The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Sergeev V, Chou F, Lam G, Hamilton C, Wilcox P, Quon B
Ann Am Thorac Soc. 2019; 17(2):147-154.
PMID: 31661636
PMC: 6993798.
DOI: 10.1513/AnnalsATS.201909-671CME.
